Horizon's Genmab drug gets blockbuster status

After the first nine months of 2021, sales of Tepezza have crossed the important USD 1bn annual sales threshold.

Rare eye disease Graves' opthalmopathy has been a big money maker for Horizon Therapeutics. | Photo: Marijan Murat/AP/Ritzau Scanpix

Horizon therapeutics has sold more than twice as much of its drug Tepezza during the first nine months of 2021 than it did during the same period last year, its Q3 report reveals.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs